⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1540765 | 1.00 | — | — | |
| SCHEMBL1114037 | 1.00 | — | — | |
| SCHEMBL1540827 | 1.00 | — | — | |
| SCHEMBL834565 | 1.00 | — | — | |
| SCHEMBL1540763 | 1.00 | — | — | |
| SCHEMBL1540762 | 1.00 | — | — | |
| SCHEMBL1114038 | 1.00 | — | — | |
| SCHEMBL1540822 | 1.00 | — | — | |
| SCHEMBL834564 | 1.00 | — | — | |
| SCHEMBL1540824 | 1.00 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2061560-A2 | BCL INHIBITORS FOR TREATING PLATELET EXCESS | Abbott Laboratories (US) | 2009-05-27 | — | — | EP | disclosed |
| WO-2008030836-A2 | BCL INHIBITORS TREATING PLATELET EXCESS | ABBOTT LABORATORIES (US) | 2008-03-13 | — | — | WO | disclosed |
| EP-1888543-A1 | APOPTOSIS PROMOTERS | ABBOTT LABORATORIES (US) | 2008-02-20 | — | — | EP | disclosed |
| WO-2006127364-A1 | APOPTOSIS PROMOTERS | ABBOTT LABORATORIES (US) | 2006-11-30 | — | — | WO | disclosed |
| WO-2005049593-A2 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | ABBOTT LABORATORIES (US) | 2005-06-02 | — | — | WO | disclosed |